Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;33(1):e13180.
doi: 10.1111/dth.13180. Epub 2019 Dec 9.

Malignant melanoma in HIV: Epidemiology, pathogenesis, and management

Alessio Facciolà  1 , Emmanuele Venanzi Rullo  1   2 , Manuela Ceccarelli  1   2 , Flavia D'Andrea  1 , Mariagiovanna Coco  1 , Cristina Micali  1 , Bruno Cacopardo  3 , Andrea Marino  3 , Serafinella P Cannavò  1 , Michelino Di Rosa  4 , Fabrizio Condorelli  5 , Giovanni F Pellicanò  6 , Claudio Guarneri  7 , Giuseppe Nunnari  1
Affiliations
Review

Malignant melanoma in HIV: Epidemiology, pathogenesis, and management

Alessio Facciolà et al. Dermatol Ther. 2020 Jan.

Abstract

People affected by immunodeficiency, and especially those infected by HIV, are burdened by a higher risk of developing malignancies. It has been estimated that the incidence of melanoma in HIV-infected people is 2.6-fold higher than in uninfected ones. In this group of patients, melanoma shows a more aggressive phenotype and poorer survival rates compared to HIV-negative people. Standard guidelines of diagnosis and care do not exist yet. Studies suggest high index of suspicion and a low threshold for biopsy in HIV-positive patients regardless of their CD4+ count and the use of standard surgical margins for re-excision procedures. In case of diagnosis of melanoma in HIV-positive patients, a thorough search for metastatic disease is recommended because of the more aggressive course of this cancer in HIV-positive patients. Moreover, to rapidly find out any recurrence or metastatic disease after treatment, these patients need a close follow-up, every 3 months, for the first 2 years and at least twice yearly thereafter. Although surgery remains the main therapeutic option, application of immune checkpoint-based immunotherapy is being studied and seems to be promising. The aim of this review is to present the current knowledge and future options for melanoma diagnosis and treatment in people living with HIV.

Keywords: HIV; immune checkpoint-based immunotherapy; malignant melanoma.

PubMed Disclaimer

References

REFERENCES

    1. American Cancer Society. (2019, January 28). Key Statistics for Melanoma Skin Cancer. Retrieved from http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-...
    1. Andersson, T. M. L., Eriksson, H., Hansson, J., Månsson-Brahme, E., Dickman, P. W., Eloranta, S., … Lambert, P. C. (2014). Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study. Cancer Epidemiology, 38(1), 93-99. http://doi.org/10.1016/j.canep.2013.12.006
    1. Andreeva, V. A., & Cockburn, M. G. (2011). Cutaneous melanoma and other skin cancer screening among Hispanics in the United States: A review of the evidence, disparities, and need for expanding the intervention and research agendas. Archives of Dermatology, 147(6), 743-745. http://doi.org/10.1001/archdermatol.2011.140
    1. Annessi, G., Bono, R., Sampogna, F., Faraggiana, T., & Abeni, D. (2007). Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: The importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. Journal of the American Academy of Dermatology, 56(5), 759-767. http://doi.org/10.1016/j.jaad.2007.01.014
    1. Anzai, S., Anan, T., Kai, Y., Goto, M., Arakawa, S., Shimizu, F., … Fujiwara, S. (2005). Skin cancer screening on a fishing island and in an inland agricultural area of Japan. The Journal of Dermatology, 32(11), 875-882.